Skip to main content
Premium Trial:

Request an Annual Quote

Stratagene Revenue Grows 16 Percent in Second Quarter

NEW YORK, Aug. 13 (GenomeWeb News) - Stratagene, a developer, manufacturer and marketer of life science research and immunodiagnostics products, announced today that its second quarter revenues grew 16 percent to $19.7 million, compared with $17.0 million in the second quarter of 2003.


For the second quarter, Stratagene generated a net income of $1.5 million, or $.08 per diluted share, an increase compared with $1.1 million, or $.07 per diluted share in the same quarter of last year.


Research and development spending during the three months ending June 30 totaled $2.81 million - up compared to $2.75 million during the same period last year.


Results for the second quarter and first half of 2004 were impacted by one-time expenses of $2.4 million associated with the merger of the company with Hycor Biomedical on  June 3 .


The company's cash, cash equivalents and marketable securities were $8.5 million

during the second quarter, and total assets were $85.7 million.


The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.